Pages that link to "Q36964464"
Jump to navigation
Jump to search
The following pages link to Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma (Q36964464):
Displaying 6 items.
- Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans (Q36060239) (← links)
- Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma (Q36074023) (← links)
- Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients? (Q37534534) (← links)
- Mantle cell lymphoma: are current therapies changing the course of disease? (Q37579294) (← links)
- Second-line treatment paradigms for diffuse large B-cell lymphomas (Q37579299) (← links)
- Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia (Q61774244) (← links)